Increased serum concentrations of soluble CD95/Fas and caspase 1/ICE in patients with acute angina

Heart

Volumn 90, Issue 2, 2004, Pages 151-154

  Ankersmit, H J ^a,b,d   Weber, T ^c   Auer, J ^c   Roth, G ^b   Brunner, M ^b   Kvas, E ^c   Moser, B ^b   Spreitzer, S ^c   Lassnig, E ^c   Maurer, E ^c   Hartl, P ^c   Wolner, E ^b   Boltz Nitulescu, G ^a   Eber, B ^c  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c Krankenhaus der Barmherzigen Schwestern Wien Betriebsgesellschaft   (Austria)

^d NONE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CD178 ANTIGEN; FAS ANTIGEN; INTERLEUKIN 1BETA CONVERTING ENZYME; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG;

ANGINA PECTORIS; ANTIGEN EXPRESSION; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DEATH; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STABLE ANGINA PECTORIS;

EID: 9144274927     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2003.012062     Document Type: Article

References (27)

1. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999;340:115-26.
2. Hansson GK. Immune mechanisms in atherosclerosis. Artherioscler Thromb Vasc Biol 2001;21:1876-90.
3. Leinonen M, Saikku P. Evidence for infectious agents in cardiovascular disease and atherosclerosis. Lancet Infect Dis 2002;2:11-7.
4. Gurfinkel E. Link between intracellular pathogens and cardiovascular diseases. Clin Microbiol Infect 1998;4:S33-6.
5. Frostegard J, Ulfgren AK, Nyberg P, et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 1999;145:33-45.
6. Koukkunen H, Penttila K, Kemppainen A, et al. C-reactive protein, fibrinogen, interleukin-6 and tumour necrosis factor-alpha in the prognostic classification of unstable angina pectoris. Ann Med 2001;33:37-47.
7. Gill C, Mestril R, Samali A. Losing heart: the role of apoptosis in heart disease: a novel therapeutic target? FASEB J 2002;16:135-46.
8. Bennett MR. Apoptosis in the cardiovascular system. Heart 2002;87:480-7.
9. Boyle JJ, Bowyer DE, Weissberg PL, et al. Human blood-derived macrophages induce apoptosis in human plaque-derived vascular smooth muscle cells by Fas-ligand/Fas interactions. Arterioscler Thromb Vasc Biol 2001;21:1402-7.
10. Nakajima T, Schulte S, Warrington KJ, et al. T-cell-mediated lysis of endothelial cells in acute coronary syndromes. Circulation 2002;105:570-5.
11. Mallat Z, Benamer H, Hugel B, et al. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation 2000;101:841-3.
12. Braunwald E. Unstable angina: a classification. Circulation 1989;80:410-4.
13. Sullivan DR, Warwick TH, Freedman SB. A new method of scoring coronary angiograms to reflect extent of coronary atherosclerosis and improve correlation with major risk factors. Am Heart J 1990;119:1262-7.
14. Nicholson DW, Ali A, Thornberry NA, et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 1995;376:37-43.
15. Los M, Stroh C, Janicke RU, et al. Caspases: more than just killers? Trends Immunol 2001;22:31-4.
16. Thornberry NA, Molineaux SM. Interleukin-1β converting enzyme: a novel cysteine protease required for IL-1β production and implicated in programmed cell death. Protein Sci 1995;4:3-12.
17. Gu Y, Kuida K, Tsutsui H, et al. Activation of IFN-γ inducing factor mediated by IL-1β converting enzyme. Science 1997;275:206-9.
18. Schonbeck U, Herzberg M, Petersen A, et al. Human vascular smooth muscle express interleukin-1β converting enzyme (ICE), but inhibit processing of interleukin-1β precursor by ICE. J Exp Med 1997;185:1287-94.
19. Kid VJ. Proteolytic activities that mediate apoptosis. Annu Rev Physiol 1998;60:533-73.
20. Kühnel F, Zender L, Paul Y et al. NFκB mediates apoptosis through transcriptional activation of Fas (CD95) in adenoviral hepatitis. J Biol Chem 2000;275:6421-7.
21. Vaux DL, Silke J. Mammalian mitochondrial IAP binding proteins. Biochem Biophys Res Commun 2003;304:499-504.
22. Cheng J, Zhou T, Liu C, et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994;263:1759-62.
23. Wang T, Chunming D, Stevenson SC, et al. Overexpression of soluble Fas attenuates transplant arteriosclerosis in rat aortic allografts. Circulation 2002;106:1536-42.
24. Hebert MJ, Masse M, Vigneault N, et al. Soluble Fas is a marker of coronary artery disease in patients with end-stage renal disease. Am J Kidney Dis 2001;38:1271-6.
25. Sata M, Walsh K. TNF-α regulation of Fas ligand expression on the vascular endothelium modulates leukocyte extravasation. Nat Med 1998;4:415-20.
26. Tanaka M, Suda T, Haze K, et al. Fas ligand in human serum. Nat Med 1996;2:317-22.
27. Okura T, Watanabe S, Jiang Y, et al. Soluble Fas and atherosclerosis in hypertensive patients. J Hypertens 2002;20:895-8.